Skip to content

Abliva

Delivering mitochondrial health

  • English
    • English
    • Svenska
  • Abliva
    • This is Abliva
      • Strategy
      • Orphan Drugs
    • Board
    • Team
    • Partners
    • Relevant publications
  • Mitochondrial Diseases
    • Primary mitochondrial diseases
      • MELAS-MIDD and KSS-CPEO
      • Leigh Syndrome
      • LHON
    • Patients
    • Expanded access policy
  • Research & Development
    • Projects
      • KL1333
      • NV354
      • Early programs
    • Partnering
      • BD Contact
  • Investors
    • Financial reports
      • Annual reports
      • Interim reports
      • Other financial information
    • Financial Calendar
    • Share and owner information
    • Equity research
    • Corporate governance
      • General meeting
      • General meetings archive
    • IR contact
  • News
    • Press releases
    • Newsletters
    • Events and Presentations
      • World Mitochondrial Disease Week 2022
      • World Mitochondrial Disease Week 2021
    • Company Calendar
    • News subscription
    • Press photos
    • Media contact
    • Privacy policy
  • Contact

Press releases

  • All
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
All MARRegulatory
15 June, 2020
Regulatory

Abliva completes the directed issue of MSEK 20 to Hadean Ventures

On April 22, 2020, the Board of Directors of Abliva AB (publ) ("Abliva" or the "Company") resolved, supported by the authorization granted at the Annual General Meeting on April 25, 2019, on a directe ...
Continue reading
31 October, 2018
Regulatory

NeuroVive today announces that the subscription period for warrants of series 2018:1 will begin on Thursday, November 1

Lund, Sweden October 31 2018 - NeuroVive Pharmaceutical AB (publ) ("NeuroVive" or "the Company") (Nasdaq Stockholm: NVP, OTCQX: NEVPF) announces today that the subscription period for the warrants of ...
Continue reading
29 May, 2018
Regulatory

Information regarding trading of warrants issued by NeuroVive

THIS DOCUMENT IS NOT TO BE DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE US, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEELAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA OR IN ANY OTHER JURISDICTION W ...
Continue reading
2 June, 2016
Regulatory

NeuroVive share upgraded to OTC Markets Group – OTCQX Best Market in the US

NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, has announced that the company's share has been upgraded to trading on the OTC Market Group's best market, OTCQX in the US. The ...
Continue reading
23 May, 2016
Regulatory

Updated timeline for conversion of NeuroVive’s BTUs into shares and warrants

NeuroVive Pharmaceutical AB (publ) announces that registration of the preferential rights issue totaling SEK 94.4 m has now been completed, and provides an updated timeline for the conversion of Neuro ...
Continue reading
26 June, 2015
Regulatory

NeuroVive share upgraded on OTC market in US

NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, has announced that the company's share has been upgraded from trading on the OTC Grey Market to OTC Pink in the US. The upgrade ...
Continue reading
11 February, 2015
Regulatory

New subsidiary secures funding of just over USD 3 m ahead of potential IPO in Taiwan

NeuroVive has established a subsidiary in Taiwan, NeuroVive Pharmaceutical Asia, Inc., which has secured initial funding totaling USD 3,255 m. The funding is sourced from Taiwanese investors, collabor ...
Continue reading
10 April, 2014
Regulatory

NeuroVive Stock Now Trading in the USA on the OTC Market

NeuroVive Pharmaceutical AB stock shares were registered with the OTC Reporting Facility for Foreign shares in New York City with the ticker symbol NEVPF:US on March 20, 2014. NeuroVive trades on the ...
Continue reading
10 April, 2013

NeuroVive First Day of Trading on NASDAQ OMX Stockholm

Lund (Sweden) – April 10, 2013, NeuroVive Pharmaceutical AB (publ), a leading mitochondrial medicine company, announces that its admission to NASDAQ OMX Stockholm will become effective and trading of ...
Continue reading
25 March, 2013

NeuroVive: NeuroVive Admitted to Trading on NASDAQ OMX Stockholm

Note: This is an English version of a press release communicated by NeuroVive 2013-03-22.
Continue reading

Popular shortcuts

Research & Development
Investors
Primary mitochondrial diseases
Interim reports

Receive updates straight to your inbox

Choose the categories that you are interested in, and check preferred language.

  1. Startpage

This is Abliva

  • Strategy
  • Board
  • Team
  • Partners and advisers
  • Relevant publications

Research & Development

  • Research & Development
  • KL1333
  • NV354
  • Early programs
  • Partnering
  • BD Contact

Investors

  • Investors
  • Annual reports
  • Interim reports
  • Other financial information
  • Financial Calendar
  • Share and owner information
  • Equity research
  • Corporate governance
  • General meeting
  • General meetings archive
  • IR contact

News

  • Press releases
  • Newsletters
  • Events and Presentations
  • Capital Markets Day 2020
  • Mitochondria Day 2020
  • News subscription
  • Press photos
  • Media contact
  • Privacy policy

Contact

Abliva AB (publ)
Medicon Village
223 81 Lund, Sweden

Phone
+46 (0)46-275 62 20

Generel questions
info@abliva.com

© Copyright 2020 – Abliva AB. All rights reserved. | We use cookies to improve our services | Cookie policy | Privacy policy

Cookies
We serve cookies. If you think that's ok, just click "Accept all". You can also choose what kind of cookies you want by clicking "Settings". Read our cookie policy
Settings Accept all
Cookies
Choose what kind of cookies to accept. Your choice will be saved for one year. Read our cookie policy
  • Necessary
    These cookies are not optional. They are needed for the website to function.
  • Statistics
    In order for us to improve the website's functionality and structure, based on how the website is used.
  • Experience
    In order for our website to perform as well as possible during your visit. If you refuse these cookies, some functionality will disappear from the website.
  • Marketing
    By sharing your interests and behavior as you visit our site, you increase the chance of seeing personalized content and offers.
Save Accept all